Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -38.31% is 26% above its 5-year average of -51.76%, near the high end of its 5-year range (-134.14%–-23.81%).
0.04% above its 12-month average of -38.33%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -10.54%.
RETURN ON ASSETS (ROA)
-38.31%
RETURN ON ASSETS (ROA) AVG TTM
-38.33%
RETURN ON ASSETS (ROA) AVG 3Y
-38.15%
RETURN ON ASSETS (ROA) AVG 5Y
-51.76%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+0.04%
CURRENT VS 3Y AVG
-0.42%
CURRENT VS 5Y AVG
+25.98%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 850 covered companies
CURRENT VS SECTOR MEDIAN
-18.74%
vs the sector median at left
Sera Prognostics, Inc.
Market Cap
$77.91M
Return on Assets (ROA)
-38.31%
TTM Avg
-38.33%
3Y Avg
-38.15%
5Y Avg
-51.76%
Market Cap
$77.38M
Return on Assets (ROA)
-136.52%
TTM Avg
-104.53%
3Y Avg
-92.09%
5Y Avg
-76.74%
Market Cap
$78.65M
Return on Assets (ROA)
-5.43%
TTM Avg
-39.13%
3Y Avg
-79.92%
5Y Avg
-71.36%
Market Cap
$77.08M
Return on Assets (ROA)
-41.94%
TTM Avg
-38.20%
3Y Avg
-35.26%
5Y Avg
-28.99%
Market Cap
$79.09M
Return on Assets (ROA)
-902.18%
TTM Avg
-2200.93%
3Y Avg
-2200.93%
5Y Avg
-2200.93%
Market Cap
$76.56M
Return on Assets (ROA)
-30.65%
TTM Avg
-38.63%
3Y Avg
-43.27%
5Y Avg
-38.60%
Market Cap
$76.48M
Return on Assets (ROA)
-55.32%
TTM Avg
-66.75%
3Y Avg
-58.76%
5Y Avg
-49.95%
Market Cap
$75.75M
Return on Assets (ROA)
-5.84%
TTM Avg
-3.07%
3Y Avg
-3.13%
5Y Avg
-9.45%
Market Cap
$80.47M
Return on Assets (ROA)
-74.91%
TTM Avg
-50.52%
3Y Avg
-40.48%
5Y Avg
-70.00%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Sera Prognostics, Inc. (SERA) | $77.91M | -38.31% | -38.33% | -38.15% | -51.76% |
| Inovio Pharmaceuticals, Inc. (INO)vs › | $77.38M | -136.52% | -104.53% | -92.09% | -76.74% |
| vTv Therapeutics Inc. (VTVT)vs › | $78.65M | -5.43% | -39.13% | -79.92% | -71.36% |
| Pulmonx Corporation (LUNG)vs › | $77.08M | -41.94% | -38.20% | -35.26% | -28.99% |
| Neonc Technologies Holdings, Inc. (NTHI)vs › | $79.09M | -902.18% | -2200.93% | -2200.93% | -2200.93% |
| Outset Medical, Inc. (OM)vs › | $76.56M | -30.65% | -38.63% | -43.27% | -38.60% |
| Hyperfine, Inc. (HYPR)vs › | $76.48M | -55.32% | -66.75% | -58.76% | -49.95% |
| SkinHealth Systems Inc. (SKIN)vs › | $75.75M | -5.84% | -3.07% | -3.13% | -9.45% |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $80.47M | -74.91% | -50.52% | -40.48% | -70.00% |
| Citius Oncology, Inc. (CTOR)vs › | $80.84M | -41.09% | -24.80% | -25.41% | -25.41% |
ROA
-38.3%
ROE
-56.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -31.32% |
| 2024-12-31 | -45.33% |
| 2023-12-31 | -37.97% |
| 2022-12-31 | -37.98% |
| 2021-12-31 | -23.81% |
| 2020-12-31 | -134.14% |
| 2019-12-31 | -71.03% |
